logo
  

ViiV Enters Collaboration And License Agreement With Shionogi To Develop HIV Integrase Inhibitor

ViiV Healthcare announced an exclusive collaboration and license agreement with Shionogi & Co. Ltd. for S-365598, an investigational integrase strand transfer inhibitor with potential for use in ultra long-acting HIV regimens. ViiV Healthcare and Shionogi plan to begin first time in human studies with S-365598 by 2023.

ViiV Healthcare will make an upfront payment of 20 million pounds to Shionogi, a 15 million pounds payment for the achievement of a clinical development milestone and royalties on net sales.

"With today's announcement about the in-licensing of a third integrase inhibitor from Shionogi, we will continue this collaboration and explore the potential of S-365598 to anchor ViiV Healthcare's pipeline beyond 2030," Kimberly Smith, Head of Research & Development at ViiV Healthcare said.

ViiV Healthcare is a global specialist HIV company majority owned by GlaxoSmithKline, with Pfizer and Shionogi as shareholders.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
This Black Friday and the following holiday season, retailers across the United States are urged to keep up their inventory amid expected surge in shopping as majority of Americans wait till last minute to fill their baskets, according to certain studies. A new Oracle Retail survey, which was conducted last week and presented earlier this week, showed that 66 percent of consumers were less than Eagle, Idaho -based Flagship Food Group is recalling certain TJ Farms Select brand frozen cauliflower, citing the potential to be contaminated with Listeria monocytogenes, the U.S. Food and Drug Administration said. The recall involves a limited number of cases of TJ Farms Select cauliflower that comes in 16 oz. packages with lot code 2077890089 and UPC code 75544000604-3. The U.S. Food and Drug Administration has approved Takeda Pharmaceuticals Co. Ltd.'s Livtencity (maribavir) as the first drug to treat post-transplant cytomegalovirus or CMV in adults and pediatric patients. The approval is to treat patients 12 years of age and older and weighing at least 35 kilograms with post-transplant CMV infection/disease that does not respond...
Follow RTT